Showing results (161-170 of 217) with videos related to
Sort By:
Pageof 22
Journal of Diabetes Science and Technology|January 9, 2025
Advancing Monogenic Diabetes Research and Clinical Care by Creating a Data Commons: The Precision Diabetes Consortium (PREDICT)Michael E McCullough, Lisa R Letourneau-Freiberg, Rochelle N Naylor, et al.Journal of Pain and Symptom Management|May 4, 2020
Racial and Ethnic Differences in Communication and Care for Children With Advanced CancerJennifer W Mack, Hajime Uno, Clare J Twist, et al.Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force reportTom Monclair, Garrett M Brodeur, Peter F Ambros, et al.The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|September 11, 2014
Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology GroupRisa Teshiba, Shinya Kawano, Larry L Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.Cancer|October 5, 2019
Unrealistic parental expectations for cure in poor-prognosis childhood cancerJennifer W Mack, Angel M Cronin, Hajime Uno, et al.Pageof 22